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Abstract
Young women in sub-Saharan Africa are disproportionately affected by HIV, making the
development of women initiated and controlled methods of prevention, including microbicides, a
priority. Adherence is pivotal to microbicide efficacy and partner related factors are known to
impact adherence. An analysis of disclosure of gel use to sexual partners and adherence in
CAPRISA 004 women was conducted to better understand this relationship. Partner disclosure
was significantly associated with a modest 4.2 % increased adherence (71.0 vs. 66.8 %, p = 0.03).
Most women rated the experience of disclosure as positive, despite 6.7 % of partners expressing a
negative reaction. Participants who disclosed were more likely to reside with their regular partner
(14.4 vs. 8.4 %; p = 0.01) and reported consistent condom use at baseline (32.9 vs. 20.9 %; p<
0.01). Partner disclosure needs to be better understood as a potential facilitator or barrier to
microbicide adherence.
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Introduction
Young women between the ages of 15 and 24 years in sub-Saharan Africa bear a
disproportionately high prevalence of HIV compared to their male counterparts [1]. The
development of HIV prevention technologies designed for, and initiated by, women remains
a priority [2], particularly for women at high risk of HIV acquisition who are unable to
negotiate other safe sex practices with their sexual partners. Tenofovir gel, a microbicide, is
one such women-initiated technology. Protocol 004 at the Centre for the AIDS Programme
of Research in South Africa (CAPRISA) assessed the efficacy of tenofovir gel applied
vaginally in a coitally-related dosing regimen and found a 39 % reduction in HIV incidence
in women assigned to tenofovir gel [3]. The trial also demonstrated a clear relationship
between adherence and gel efficacy: low adherers (gel use \50 % of sex acts) had 28 %
efficacy, intermediate adherers (gel use 50–80 % of sex acts) had 39 % efficacy and high
adherers (gel use [80 % of sex acts) had 54 % efficacy [3]. Further, the effectiveness of the
gel increased to 74 % in women with protective drug levels [4], highlighting the importance
of adherence for microbicide effectiveness. The reasons for suboptimal adherence in
microbicidetrials are not fully understood [5]. The increasing efficacy of an intervention as
adherence increases demonstrates the importance of understanding the conditions and
factors that impact upon a woman’s ability to adhere to the prescribed dosing regimen. A
better understanding of the behavioural and social determinants that enhance adherence is
needed to develop interventions to improve adherence and thereby enhance the probability
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of demonstrating efficacy [5]. Microbicide research has focused on factors influencing
adherence, such as preferred dosage forms and regimens, stigma and male perception of
microbicide use [5]. A keysocial determinant of adherence identified among women, is the
inter-personal dynamic with their sexual partners, which critically shapes the women’s
ability to use microbicides correctly and consistently [6–10].
While the FemPreP trial [6] identified women’s perception of their risk of HIV acquisition
as a key factor impacting adherence, other predictors of poor adherence have been difficult
to identify. During adherence counseling sessions, women who had not disclosed their
participation in the CAPRISA 004 trial raised the issue that gel use prior to sex may lead to
their partners inadvertently discovering their gel use [3]. The purpose of this study was to
identify the role, if any, of male partner disclosure in influencing gel adherence in women
participating in the CAPRISA 004 trial.
Methods
CAPRISA 004 was a double-blind, randomized, placebo-controlled trial, conducted from
May 2007 to March 2010, at an urban and rural clinic in Kwazulu-Natal, South Africa. The
purpose of the trial was to assess the effectiveness of tenofovir gel in preventing HIV and
other sexually transmitted infections [3]. HIV uninfected, sexually active, non-pregnant
women (n = 889) were recruited from clients utilizing primary health care clinics for family
planning or sexually transmitted infection (STI) services [7, 8], or through community
outreach. A coitally-linked dosing strategy also referred to as BAT24 (first dose of gel
inserted up to 12 h before sex and the second as soon as possible after sex, but within 12 h;
with no more than two does in 24 h) was prescribed [3].
A structured, standardized set of questions, addressing disclosure of study participation and
gel use to the last sexual partner, was administered to women in the CAPRISA 004 trial at
their study exit visit. In October 2009, approximately half-way during the trial, the
questionnaire was amended to include additional questions on disclosure of gel use to the
last sexual partner, experience of disclosure, reactions of the sexual partner to gel use and
sexual partner reaction to disclosure.
The questionnaire was administered by trained study nurses and counselors. Training
included interviewing techniques such as being non-judgmental verbally or through body
language. The questionnaire was administered at the study exit visit in order to reduce
socially desirable responses. Study exit visits for women who acquired HIV during follow-
up was scheduled at least 90 days post-seroconversion, and for HIV uninfected participants,
at the study close-out visit or at the last study visit for participants who were being
terminated either voluntarily or for study related reasons.
Disclosure of study participation and gel use to sexual partners or anyone else, was not a
study requirement but for those women who chose to disclose gel use, additional support
was available from study staff.
Adherence was measured as previously described [3], with the primary adherence measure
being defined as the proportion of sex acts covered by two returned empty applicators based
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on the pre- and post-coital dosing regimen. The median of each woman’s monthly adherence
estimates was assigned as her overall gel adherence, assuming that every reported sex act
used two doses of gel. Data were analysed using SAS® (SAS Institute Inc., Cary, NC, USA)
Version 9.3. Data using the shorter first (pre-October 2009) version and the longer second
(post-October 2009) version of the questionnaire were combined for this analysis. Duration
of time on study was calculated from randomisation to estimated date of HIV infection, date
of withdrawal or study close-out, whichever occurred first. Categorical data were analysed
using Fisher’s exact test. Normally distributed continuous data were analysed using
Student’s t test and continuous data that were not normally distributed were analysed using
Wilcoxon’s rank sums test.
Written informed consent was obtained and regulatory oversight was provided by the
University of KwaZulu-Natal’s (UKZN) Biomedical Research Ethics Committee (BREC),
the South African Medicines Control Council and FHI 360 Protection for Human Subjects
Committee.
Results
A total of 846 (95 %) of the 889 women enrolled in CAPRISA 004 were included in this
study. Of the 43 not included, three women did not complete the question on gel disclosure
and 40 did not complete the questionnaire for various reasons including, but not limited to
loss to follow-up, participant refusal or study staff omission. Of the 846 women included in
the analysis, three did not have data on adherence. In total, 93 out of 846 (11.0 %) women
completed the shorter first version of the questionnaire and 753 out of 846 (89.0 %) women
completed the longer second version of the questionnaire.
A total of 569 (67.3 %) of the women who completed the study questionnaire reported that
they had disclosed gel use to their last sexual partner. Women who disclosed gel use to their
sexual partners were similar in age, marital status and monthly income when compared to
the women who did not disclose gel use to their sexual partners (Table 1). Women who
disclosed gel use to sexual partners were more likely to be residing with their regular partner
(14.4 vs. 8.4 %; p = 0.01) and were more likely to report consistent condom use during
sexual intercourse (32.9 vs. 20.9 %; p < 0.01) than women who did not disclose gel use to
their sexual partners.
Gel adherence was moderately higher in women who had disclosed gel use to sexual
partners (71.0 %) than in women who had not disclosed gel use (66.8 %) (RD 4.0 %, CI
0.37–7.85, p = 0.03). Adjusting for age, study site, treatment arm, condom use and living
with a regular partner did not alter this association materially.
Among the 569 women who disclosed gel use, the HIV incidence rate was 6.4 per 100
women-years compared to 9.3 per 100 women-years in the 277 women (IRR = 0.69; p =
0.08) who did not disclose gel use (Table 2). Among the women who disclosed gel use to
their sexual partners, their risk of HIV infection in the tenofovir gel arm was 33 % lower,
while in women who did not disclose their gel use to the sexual partners, their HIV risk was
44 % lower in the tenofovir gel arm compared to the placebo gel arm (Table 3). Of the 514
Mngadi et al. Page 4






















women who reported on their sexual partner’s reaction to gel use, 160 (28.1 %) said that
their sexual partners liked the gel; 262 (46.1 %) reported that their sexual partner had no
reaction to the gel; 100 (17.6 %) reported that they did not know what their sexual partner’s
reaction was, and 38 (6.7 %) reported that their sexual partners did not like the gel (Table 2).
Reported condom use at the last sex act, assessed monthly during the study, was not
associated with partner perception of gel use (p = 0.16).
Of the 515 women who disclosed gel use to their sexual partners, 296 (57.5 %) found
talking to their partner about the gel easy, 152 (29.5 %) found this conversation with their
partner difficult and 67 (13.0 %) women found the discussion about gel use neither difficult
nor easy. Overall, 342 (66.4 %) women rated disclosure of gel use to their partner as a
positive experience.
Discussion
We found a significant but modest relationship between disclosure and adherence. The
association between partner disclosure and higher adherence is supported by prior research
which found that disclosure to sexual partners of study product use was associated with
more consistent self-reported adherence [9–13]. The unreliability of self-report of product
use has been well described [6, 14]. With antiretroviral based microbicides the ability to
measure drug levels has enabled the quantification of the extent of over-reporting of product
use [6, 14, 15].
Even though partner disclosure was significantly associated with adherence, disclosure was
not related to efficacy of 1 % tenofovir gel. This suggests that other contextual and partner-
related factors are influential in the relationship between adherence and efficacy. provide
valuable clues as to the utility of facilitating such disclosure, in future microbicide research
or roll-out programmes. In this analysis the risk attributable to disclosure was 3.3 %, which
was not statistically significant, but in terms of informing a decision to include disclosure as
an adherence strategy in the rollout of the gel, this may remain important. Of note, the group
that did not disclose gel use to sexual partners, are likely to be less able to negotiate condom
use and probably have less stability in their relationships. Though the protective effect of
disclosure on incident HIV infection is not significant, it is important to note that the gel
appears to offer more protection to non-disclosing women, who may also be at increased
risk of HIV due to difficulties in negotiating safer sexual practices and lack of stability in
their sexual relationships. This speaks to the efficacy of the 1 % tenofovir gel. Women in
CAPRISA 004 were more likely to disclose product use if they were living with a regular
partner, and if they reported consistent condom use at baseline; this suggests that existing
established supportive relationship dynamics facilitated both disclosure and adherence. It
may be more difficult to promote disclosure in settings where the partner is not a long-term
regular partner or where the women are not co-habiting with their regular male partners.
The CAPRISA 004 trial was designed with a coitally-linked dosing regimen (BAT24), after
consultation with the specific study communities indicated that this strategy would yield the
greatest adherence [3]. This was coupled with an extensive adherence support program in
that same community to support women through problems encountered during actual use
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[3]. Despite this adherence program and high gel acceptability, about 40 % of the women in
this study had below 50 % gel adherence [3], [9–13]. In the CAPRISA 004 trial, women’s
overall adherence to the dosing regimen, was not affected by partners’ lack of provide
valuable clues as to the utility of facilitating such disclosure, in future microbicide research
or roll-out programmes. In this analysis the risk attributable to disclosure was 3.3 %, which
was not statistically significant, but in terms of informing a decision to include disclosure as
an adherence strategy in the rollout of the gel, this may remain important. Of note, the group
that did not disclose gel use to sexual partners, are likely to be less able to negotiate condom
use and probably have less stability in their relationships. Though the protective effect of
disclosure on incident HIV infection is not significant, it is important to note that the gel
appears to offer more protection to non-disclosing women, who may also be at increased
risk of HIV due to difficulties in negotiating safer sexual practices and lack of stability in
their sexual relationships. This speaks to the efficacy of the 1 % tenofovir gel.
Women in CAPRISA 004 were more likely to disclose product use if they were living with a
regular partner, and if they reported consistent condom use at baseline; this suggests that
existing established supportive relationship dynamics facilitated both disclosure and
adherence. It may be more difficult to promote disclosure in settings where the partner is not
a long-term regular partner or reaction to or dislike of the gel, which may be a reflection of
the effectiveness of the comprehensive adherence support activities, the neutral stance
adopted by the protocol staff with regard to disclosure, the support offered to those women
who opted to disclose, as well as the opportunity for women to use women-controlled
methods of prevention. Previous studies have found that permission from male partners to
participate in a study, consistent disclosure to and partner perception of study product use
significantly affected women’s attitudes and actions, including gel acceptability and
adherence [9–13]. The experience of partner disclosure in this analysis was good for most
women, with only the minority of disclosures received negatively by partners. This is
probably a reflection of the underlying established stable relationship dynamic, given that
women who disclosed were more likely to be living with their regular partner and more
likely to be using condoms at baseline.
Condom use throughout CAPRISA 004 was shown to be similar between the active and
placebo arms [3]. In this analysis there was a significant difference at baseline in condom
use between women who disclosed gel use and those who did not, with the former group
reporting consistently higher condom use both before and during the study. During follow-
up women who disclosed were also more likely to report condom use at last sex act (84.0 %)
and consistent condom use in the last 4 weeks (43.5 %) prior to study exit, but both were not
statistically significant. However, both the established and continued stable relationship
dynamic at baseline and during study conduct, and the unreliability of self-reported condom
use due to social desirability and deliberate misreport may also be responsible for this effect
[16].
Potential limitations of this analysis include its exploratory nature and the limited
generalizability due to the small sample size and that the study was conducted only in two
sites in Kwazulu-Natal. Furthermore, the impact of the change in the adherence support
program on disclosure cannot be assessed as disclosure was only assessed at study exit [3].
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Disclosure to the last sexual partner at study exit also does not take into account partner
changes and disclosure to all partners during the conduct of the study, neither is the timing
of disclosure known. Information on permission from the women’s male partners to join the
study was not collected and cannot be evaluated as a factor facilitating both disclosure and
adherence. Several variables, including condom usage, relied on participant self-report
collected through interviewer-administered questionnaires, and are thus subject to recall and
social desirability bias [3]. Male perception was only explored from the aspect of the women
participants’ self-report and other studies have shown that women may report male
perception according to their own beliefs of what their partners’ response might be [17].
Social harms information was not collected in sufficient detail to determine relatedness to
disclosure of gel use separately from that of study participation, which would be of great
interest in gauging the severity of negative male responses to disclosure. Strengths include
the comprehensive adherence support measures offered at every visit, the neutral supportive
stance of the staff irrespective of the woman’s decision on whether to disclose or not,
encouragement of reporting of social harms and referral for the same if required, and the
collection of disclosure data at study exit to counteract socially desirable responses in
reaction to the adherence program.
Conclusion
Partner disclosure was significantly associated with a modest improvement in adherence and
should be considered for inclusion when designing adherence programs in microbicide
research. Adherence is probably impacted by many other enhancing/facilitating contextual
factors which need further elucidation through research.
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Table 1
Baseline demographic and sexual behavioral characteristics stratified by disclosure of gel use to sexual partner
Disclosure of gel use (n = 569) Non-disclosure of geluse (n = 277) p value
Sociodemographic characteristics
 Mean age in years (range) 23.9 (18–40) 23.6 (18–39) 0.38
 Proportion of women who are rural (n) 68.7 % (391) 68.6 % (190) 1.00
 Proportion with monthly income[R1000(n) 92.3 % (525) 91.0 % (252) 0.51
 Proportion married (n) 5.8 % (33) 5.1 % (14) 0.75
 Proportion with a stable partner (n) 92.4 % (526) 92.8 % (257) 1.00
 Proportion living with a stable partner (n) 14.4 % (81) 8.4 % (257) 0.01
Sexual behavioral characteristics
 Mean age of sexual debut (SD) 17.3 (2.04) 17.5 (2.04) 0.20
 Number of lifetime sexual partners % (n)
  1 33.9 % (193) 32.5 % (90) 0.58
  2 26.7 % (152) 31.0 % (86)
  3–6 35.3 % (201) 32.1 % (89)
  7 or more 4.0 % (23) 4.3 % (12)
 New partner in past 30 days (n) 0.5 % (5) 2.2 % (6) 0.07
 Median number of reported sex acts in last 7 days (IQR) 1 (0–3) 2 (0–3) 0.93
 Mean number of sex acts per month (SD) 6 (4–10) 6 (4–12) 0.27
 Condom use during last sex act (n) 58.1 % (331) 60.0 % (165) 0.65
 Always use a condom during sex (n) 32.9 % (187) 20.9 % (58) \0.01
SD standard deviation, IQR interquartile range
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Table 3
Sexual partner’s opinion of study gel and its effect on the women’s gel adherence in the CAPRISA 004 trial
What did your partner think of the study gel? n Adherence
Median IQR
He liked it 28.1 (160) 56.9 50.0–100.0
He did not like it 6.7 (38) 63.5 50.0–100.0
He had no reaction to it 46.1 (262) 66.7 50.0–100.0
I don’t know 17.6 (100) 73.9 50.0–100.0
Other 1.1 (6) 67.0 52.3–97.2
Missing 0.5 (3) 100.0 46.7–100.0
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